Wegovy's $199 starter price ends June 30: what's next

• The $199/month NovoCare savings offer for injectable Wegovy starter doses (0.25 mg and 0.5 mg) covers 2 monthly fills through June 30, 2026.
• Starting July 1: the standard NovoCare self-pay price is $349/month for injectable Wegovy (all doses 0.25–2.4 mg) and $399/month for Wegovy HD (7.2 mg).
• The oral Wegovy tablet has a separate savings structure: $149/month for 1.5 mg and 4 mg doses, with the 4 mg pricing available through August 31, 2026, then shifting to $199/month for 4 mg.
• Medicare patients: the CMS GLP-1 Bridge launches July 1 at $50/month for eligible beneficiaries — a separate program from NovoCare.
• List price for Wegovy without any savings program is approximately $1,350/month.

Novo Nordisk's introductory savings offer was always time-limited. Per NovoCare's terms, patients new to the Wegovy Savings Offer pay $199 for each of the first 2 monthly fills of 0.25 mg or 0.5 mg injectable doses, through June 30, 2026. After that, the NovoCare self-pay price applies:

These prices apply to patients filling through NovoCare specialty pharmacy without commercial insurance. Patients with commercial insurance coverage for Wegovy may pay different amounts depending on their plan.

A note on the oral tablet pricing: the brief for this article cited $199/month for oral Wegovy through August 31. The verified NovoCare price is $149/month for the 1.5 mg and 4 mg starter doses — with the 4 mg discount available through August 31, 2026, after which it rises to $199/month. This is the accurate, primary-source-verified figure.

The price change primarily affects:

• Patients on injectable Wegovy starter doses who have been using the introductory offer and are paying $199/month
• Uninsured patients or those whose insurance does not cover Wegovy for weight management
• Patients who transitioned from compounded semaglutide to branded Wegovy expecting a similar cost profile

Patients with commercial insurance that actively covers Wegovy on the formulary pay different amounts determined by their plan — this change in the NovoCare self-pay price does not directly affect them.

The oral Wegovy tablet (semaglutide) is on a separate pricing schedule. Through August 31, 2026, the 4 mg oral dose is available at $149/month through NovoCare. After that date, the 4 mg price rises to $199/month. The 1.5 mg (starting dose) stays at $149/month.

The oral tablet has the same active ingredient as injectable Wegovy but requires a strict fasting protocol: taken after an 8-hour fast with only a sip of water, then no food or drink for 30 minutes afterward. This is a meaningful daily constraint for some patients.

The US FDA-approved oral GLP-1 without a fasting requirement is Foundayo (orforglipron), a different compound.

Starting July 1, 2026, eligible Medicare Part D beneficiaries can access Wegovy (both injectable and tablet) through the new CMS GLP-1 Bridge at a flat $50/month copay.

To be eligible for the Bridge, beneficiaries generally need:

• BMI of 35 or higher, or
• BMI of 30+ with heart failure, uncontrolled hypertension, or chronic kidney disease, or
• BMI of 27+ with pre-diabetes, prior heart attack, or peripheral artery disease

Prior authorization through CMS's central processor is required. You cannot use the NovoCare savings card and the Medicare Bridge simultaneously. If you are on Medicare, the Bridge may offer substantially better pricing than NovoCare self-pay.

Commercial insurance coverage: GLP-1 coverage varies significantly by employer and plan. Some plans have recently dropped Wegovy coverage; others have added it. Review your current formulary or contact your benefits team.

Manufacturer savings card (non-NovoCare): Patients with commercial insurance can use the Wegovy savings card at retail pharmacies (not just NovoCare) to pay as little as $25/month, subject to eligibility and a maximum monthly savings of $100. Government beneficiaries are excluded.

Patient assistance programs: Novo Nordisk has income-based patient assistance programs for uninsured patients who cannot afford medication. Eligibility requirements and application processes apply.

Telehealth and other GLP-1 options: The GLP-1 landscape has changed significantly since 2024. The FDA-approved oral option (Foundayo) may be worth discussing with your prescriber as an alternative depending on your health profile and insurance situation.

• Whether Novo Nordisk will extend, modify, or replace the $199/month injectable savings offer after June 30
• Whether the oral Wegovy 4 mg savings offer will be extended past August 31, 2026
• How employer plan formularies will continue to evolve on GLP-1 coverage in the second half of 2026

• Does my insurance cover injectable Wegovy for weight management? Is there a step therapy or prior authorization requirement?
• Do I qualify for the Medicare GLP-1 Bridge starting July 1?
• Am I eligible for the Wegovy savings card at my regular retail pharmacy, and how does that compare to NovoCare self-pay?
• Given the cost change, is the oral Wegovy tablet or another FDA-approved option worth considering for my situation?

July 1 is a real inflection point for patients who have been on the $199/month introductory offer. At $349/month, the new NovoCare self-pay rate is a meaningful cost increase for anyone paying out of pocket.

The most important step is making a decision before your next refill — not when you run out. Call your prescriber or pharmacist now to understand whether your insurance covers Wegovy, whether you qualify for the Medicare Bridge, and what your actual July 1 cost will be.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Wegovy.com: Savings and coverage options
• NovoCare Pharmacy: Pricing and offer terms (June 2026)
• CMS: Medicare GLP-1 Bridge — eligibility and coverage